CLINICAL EVALUATION OF BIOCHEMICAL MARKERS IN HEPATITIS C AND ASSOCIATED LIVER DISEASES

Abstract

Hepatitis C is a significant liver disease, which may progress from minimal hepatic inflammation to fibrosis and cirrhosis. Laboratory measures give valuable information about liver damage, dysfunction and disease progression. This research examined biochemical marker profiles in a Hepatitis C dataset of blood donors, hepatitis, fibrosis and cirrhosis cases. Biochemical markers, such as AST, BIL, GGT, ALB, CHE, CREA, ALT, ALP, CHOL and PROT were evaluated using descriptive statistics, group comparison, trend analysis, and cirrhosis deviation. Biochemical differences between groups were observed. The highest variation was observed in cirrhosis cases, with an increase in AST, BIL, GGT, and CREA and decrease in ALB and CHE compared to blood donor group. These suggest that severe liver damage is linked to multiple biochemical dysfunction related to liver cell damage, bile metabolism, decreased synthetic capacity, and potentially other systems. The research demonstrates the potential of biochemical profiling as a feasible and understandable means of evaluating the impact of Hepatitis C-associated liver disease. While conventional markers should not be used to diagnose liver disease, their integrated assessment may contribute to early identification, follow-up, and risk assessment of progressive liver disease.